Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2014. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Annual Bonus Plan (DABP) post-tax awards for the 2013 bonus year.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for the company. Instead, it details specific performance thresholds used for executive compensation vesting:
- Adjusted Free Cash Flow Thresholds: Vesting ranges from 0% (below £13.68bn) to 100% (at £16.22bn).
- Transaction Price: Co-Investment Shares were acquired at an ADS price of US$54.35 on March 14, 2014.
- Award Details: Ms. D. Connelly received 1,033 ADSs underlying Co-Investment Shares.
Material Changes
The filing does not disclose material changes to the company's financial position or operations compared to prior periods. It reports a specific corporate action: the grant of Matching Awards to a US participant (Ms. D. Connelly) on a post-tax basis, approved by the Remuneration Committee on February 12, 2014, and executed on March 14, 2014.
Guidance, Outlook, and Risks
Performance Measures and Vesting Conditions: The Matching Award vesting is contingent on three equally weighted measures over a three-year period (January 1, 2014, to December 31, 2016):
- Total Shareholder Return (TSR): Relative performance against a comparator group of 10 global pharmaceutical companies. Vesting is 0% if ranked 6th or below, 44% if ranked 5th, and maximum if ranked 1st-3rd.
- Adjusted Free Cash Flow: Tiered vesting based on achieving specific cash flow targets (£13.68bn to £16.22bn).
- R&D New Product Performance: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 122% of the threshold.
Risks: The primary risk highlighted is that conditional awards will lapse if performance conditions are not met by the end of the performance period. Dividends accrue on shares but only vest if the underlying shares vest.
Key Facts for Investor Verification
- Verify the specific performance targets for the R&D new product measure, as they are currently undisclosed.
- Monitor the company's ranking within the TSR comparator group (AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings, Sanofi, and GSK) to assess potential vesting outcomes.
- Track future Adjusted Free Cash Flow results against the £13.68bn to £16.22bn vesting thresholds.
- Note that this filing relates to a specific executive transaction and does not contain full financial statements for the period.